In its first round of Series C fundraising, Ubie, Inc., a healthcare AI firm with the goal of “Developing a Healthcare Guide for Everyone,” raised $26.2 million. The Dai-ichi Life Insurance Company, Limited, Egg FORWARD, Inc., Norinchukin Capital Co., Ltd., and NVenture Capital Limited, fully owned subsidiaries of NEC Capital Solutions Limited, are among the new investors in the round. SUZUKEN CO., LTD. is one of the round’s existing participants. Ubie has raised $59.8 million to far.
One of the rare firms with a medical data platform that interacts directly with both patients and healthcare organizations is Ubie. Utilizing AI as its primary technology, Ubie provides two services that emphasize the “medical questionnaire” as a doorway to healthcare.
Patients are given access to a “AI-powered symptom checker” that asks roughly 20 questions about their symptoms in order to identify associated disorders and deliver more thorough useful health information. It has gained the trust of 5 million users each month since its introduction, including those in Japan and the US.
Ubie provides medical institutions with “AI-powered patient intake,” a solution that speeds up the medical interview procedure. This service is based on a database that was assembled by more than 50 practicing doctors and contains over 50,000 medical articles from all over the world. More than 1,000 medical facilities throughout the world have used the service, which has increased their operational effectiveness.
By establishing connections between patients, healthcare providers, and pharmaceutical firms via the medical data platform it is developing, Ubie will seek to address the following medical challenges in Japan and the U.S.
- Make sure that patients go to the right hospital at the right time.
- Make sure that doctors have access to current, pertinent knowledge from the vast amount of research on illnesses and rare diseases outside of their field of expertise.
- Make sure that pharmaceutical companies continue to give patients the right information and scientific findings about their conditions.
In order to create a medical data platform that links patients, healthcare organizations, and pharmaceutical firms, Series C money will be utilized to support company expansion in both Japan and the United States.
Yoshinori Abe, MD, the co-founder, and CEO of Ubie, stated: “The existing healthcare system is suffering from different losses owing to the fragmentation of information owned by patients, medical institutions, and pharmaceutical corporations, not only in Japan but also in other countries. With the use of Ubie’s data platform, this fundraising initiative intends to quicken collaboration with pharmaceutical firms and develop an unmatched patient-centered medical experience. Ubie already conducts business with more than 20 significant pharmaceutical firms in Japan and other nations, which advances Ubie’s goal of creating a universal healthcare manual.
